A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

NCT07491497 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

ALK-positive NSCLC
ALK-Positive Lung Cancer
ALK-positive Non-small Cell Lung Cancer

Interventions

DRUG: TRI-611

Sponsor

TRIANA Biomedicines, Inc.